Tennessee is currently home to 1989 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Baptist Cancer Center, Memphis, Tennessee
Conditions: Solid Tumors, GI Cancer
Register for Updates
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Recruiting
The MIDAS study aims to follow LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Lymphangioleiomyomatosis
Register for Updates
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients With Dry Eye
NCT05201170
Recruiting
This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an opthalmic solution to determine if safe and efficacious for dry eye patients. After a 2-week run-in period, patients will be randomized equally to the PL9643 opthalmic solution or vehicle opthalmic solution administered bilaterally three times a day for 12 weeks. A Data Monitoring Committee will be engaged to review interim data.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/08/2022
Locations: Palatin Clinical Site #2, Memphis, Tennessee
Conditions: Dry Eye, Dry Eye Syndromes
Register for Updates
Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors
NCT04990739
Recruiting
MetaboMed is developing MTB-9655, an orally bioavailable, first-in-class small molecule inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 (ACSS2) enzyme, as a potential treatment for patients with cancer. This study is a Phase 1,First-in-Human (FIH), open-label dose-escalation study of MTB-9655 given daily as a single oral (PO) agent. Up to 30 patients with locally advanced, unresectable and/or metastatic solid tumor(s) are expected to be enrolled in the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/15/2021
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Advanced Solid Tumor
Register for Updates
MAP Autism Prediction Study
NCT04672967
Recruiting
This pilot clinical trial tests the hypothesis that certain blood metabolite levels can be used to predict Autism Spectrum Disorder (ASD). The study cohort will consist of 200 participants between the ages 18 and 60 months who have been referred to a developmental pediatric center for clinical evaluation of ASD or other developmental delay. Two selected sites will enroll 75 participants each with another 50 typically developing participants. Participants will receive a physical exam (including a... Read More
Gender:
All
Ages:
Between 18 months and 60 months
Trial Updated:
11/03/2021
Locations: VUMC, Nashville, Tennessee
Conditions: Autism Spectrum Disorder, Developmental Delay
Register for Updates
Skincare Products and Environmental Health
NCT04836364
Recruiting
The purpose of this study is to explore the potential for an association between the development of prepubertal gynecomastia and history exposure to lavender essential oil, tea tree essential oil, and other essential oils.
Gender:
All
Ages:
Between 2 years and 15 years
Trial Updated:
10/29/2021
Locations: Franklin Health Research Center, Franklin, Tennessee
Conditions: Gynecomastia, Endocrine System Diseases
Register for Updates
Awareness Enhancing Interventions
NCT04683510
Recruiting
The purpose of this study is to determine if increasing awareness and, thus, enhancing positive attitudes about research, prior to recruitment attempts, will increase participation in cancer clinical research among African American (AA) cancer survivors so that recruitment efforts can focus on the most optimal and cost- effective approaches
Gender:
All
Ages:
50 years and above
Trial Updated:
10/19/2021
Locations: University of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Research Awareness
Register for Updates
Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study
NCT05026658
Recruiting
Visual acuity is the relative ability of the eye to resolve detail that is usually expressed as the reciprocal of the minimum angular separation in minutes of two lines just resolvable as separate and that forms in the average human eye an angle of one minute. Visibly Inc. has developed a method for determining a patient's visual acuity electronically via a web-based software system that can be self-administered wherever convenient. This method provides an efficient alternative for people to ha... Read More
Gender:
All
Ages:
Between 22 years and 40 years
Trial Updated:
09/17/2021
Locations: Total Eye Care, Memphis, Tennessee
Conditions: Digital Acuity Product
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee
Conditions: Diabetes
Register for Updates
A Tailored, Health Communication Intervention for HPV Vaccine Hesitant Families
NCT04380623
Recruiting
The human papillomavirus (HPV) causes 90% of cervical cancers and is implicated in multiple other cancers. The HPV vaccine can prevent the vast majority of these cancers, but it is underused in adolescents, especially among those within vaccine hesitant (VH) parents. The proposed research is to develop and pilot test a tailored, health communication intervention aimed to increase HPV vaccination among VH parents. The proposed research is innovative because no evidence-based health communication... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2021
Locations: Meharry Medical College, Nashville, Tennessee
Conditions: Human Papilloma Virus, HPV-Related Carcinoma, Vaccine Refusal, Parents, Program, Communication
Register for Updates
Middle-ear Reflex Testing Using Wideband Acoustic Immittance
NCT04875637
Recruiting
This project will assess the middle-ear muscle reflex using wideband acoustic immittance which is a valuable method for evaluating infants, children, and adults. The developments will facilitate clinical applications that include hearing screening and diagnostic evaluation of persons of all ages with normal hearing and with hearing loss.
Gender:
All
Ages:
All
Trial Updated:
07/30/2021
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Hearing Disorders
Register for Updates
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
NCT04948151
Recruiting
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.
Gender:
Female
Ages:
21 years and above
Trial Updated:
06/24/2021
Locations: ClinSearch, Chattanooga, Tennessee
Conditions: Female Sexual Arousal Disorder
Register for Updates